BCAB (BioAtla) Loans Receivable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioAtla Loans Receivable?

BioAtla's Loans Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

BioAtla Loans Receivable Historical Data

The historical data trend for BioAtla's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAtla Loans Receivable Chart

BioAtla Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Loans Receivable

Get a 7-Day Free Trial

BioAtla Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

BioAtla Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

BioAtla Loans Receivable Related Terms

Thank you for viewing the detailed overview of BioAtla's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAtla Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

11085 Torreyana Road, San Diego, CA, USA, 92121

Website

https://www.bioatla.com

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Executives

Sylvia Mcbrinn	director
Short Jay M Phd	director, 10 percent owner, officer: Chief Executive Officer	C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez	officer: See Remarks	121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams	director	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith	director, officer: President	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers	officer: Chief Medical Officer	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron	officer: Chief Financial Officer	901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy	director, 10 percent owner	C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc	10 percent owner	104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc	10 percent owner	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran	director	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short	10 percent owner, officer: See Remarks	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142